Pearl Therapeutics Secures $65,000,000 Series D Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=8e8a109a-13b8-4d3a-8aa0-2319d959b2e7&Preview=1 -
Date
11/13/2012 -
Company Name
Pearl Therapeutics -
Mailing Address
200 Saginaw Drive Redwood City, CA 94063 -
Company Description
Pearl Therapeutics is focused on developing a pipeline of novel and
superior products for chronic respiratory disorders, providing patients
with advanced therapeutic options in familiar and well accepted dosage
forms. The company has licensed advanced particle technology from Nektar
Therapeutics (Nasdaq: NKTR) for developing a series of products in selected
therapeutic fields. -
Website
http://www.pearltherapeutics.com -
Transaction Type
Venture Equity -
Transaction Amount
$65,000,000 -
Transaction Round
Series D -
Proceeds Purposes
Proceeds from this financing will be used by Pearl to start Phase 3 for PT003, Pearl’s lead candidate product comprised of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA) and formoterol fumarate (FF), a long-acting beta-2 agonist (LABA) delivered via a metered dose inhaler (HFA MDI). -
M&A Terms
-
Venture Investor
Vatera Healthcare Partners -
Venture Investor
5AM Ventures -
Venture Investor
New Leaf Venture Partners -
Venture Investor
Clarus Ventures
